Copyright Reports & Markets. All rights reserved.

Global Peptide Vaccine for Tumor Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032

Request for Sample of this report
Buy now

1 Market Overview

  • 1.1 Product Overview and Scope
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Market Analysis by Type
    • 1.3.1 Overview: Global Peptide Vaccine for Tumor Consumption Value by Type: 2021 Versus 2025 Versus 2032
    • 1.3.2 Synthetic Polypeptide Vaccines
    • 1.3.3 Recombinant Polypeptide Vaccine
    • 1.3.4 Others
  • 1.4 Market Analysis by Application
    • 1.4.1 Overview: Global Peptide Vaccine for Tumor Consumption Value by Application: 2021 Versus 2025 Versus 2032
    • 1.4.2 Infectious Disease Prevention
    • 1.4.3 Cancer Immunotherapy
    • 1.4.4 Others
  • 1.5 Global Peptide Vaccine for Tumor Market Size & Forecast
    • 1.5.1 Global Peptide Vaccine for Tumor Consumption Value (2021 & 2025 & 2032)
    • 1.5.2 Global Peptide Vaccine for Tumor Sales Quantity (2021-2032)
    • 1.5.3 Global Peptide Vaccine for Tumor Average Price (2021-2032)

2 Manufacturers Profiles

  • 2.1 AmbioPharm
    • 2.1.1 AmbioPharm Details
    • 2.1.2 AmbioPharm Major Business
    • 2.1.3 AmbioPharm Peptide Vaccine for Tumor Product and Services
    • 2.1.4 AmbioPharm Peptide Vaccine for Tumor Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.1.5 AmbioPharm Recent Developments/Updates
  • 2.2 Almac
    • 2.2.1 Almac Details
    • 2.2.2 Almac Major Business
    • 2.2.3 Almac Peptide Vaccine for Tumor Product and Services
    • 2.2.4 Almac Peptide Vaccine for Tumor Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.2.5 Almac Recent Developments/Updates
  • 2.3 ACT
    • 2.3.1 ACT Details
    • 2.3.2 ACT Major Business
    • 2.3.3 ACT Peptide Vaccine for Tumor Product and Services
    • 2.3.4 ACT Peptide Vaccine for Tumor Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.3.5 ACT Recent Developments/Updates
  • 2.4 Ultimovacs
    • 2.4.1 Ultimovacs Details
    • 2.4.2 Ultimovacs Major Business
    • 2.4.3 Ultimovacs Peptide Vaccine for Tumor Product and Services
    • 2.4.4 Ultimovacs Peptide Vaccine for Tumor Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.4.5 Ultimovacs Recent Developments/Updates
  • 2.5 Marker Therapeutics, Inc.
    • 2.5.1 Marker Therapeutics, Inc. Details
    • 2.5.2 Marker Therapeutics, Inc. Major Business
    • 2.5.3 Marker Therapeutics, Inc. Peptide Vaccine for Tumor Product and Services
    • 2.5.4 Marker Therapeutics, Inc. Peptide Vaccine for Tumor Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.5.5 Marker Therapeutics, Inc. Recent Developments/Updates
  • 2.6 Immatics
    • 2.6.1 Immatics Details
    • 2.6.2 Immatics Major Business
    • 2.6.3 Immatics Peptide Vaccine for Tumor Product and Services
    • 2.6.4 Immatics Peptide Vaccine for Tumor Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.6.5 Immatics Recent Developments/Updates
  • 2.7 OncoPep
    • 2.7.1 OncoPep Details
    • 2.7.2 OncoPep Major Business
    • 2.7.3 OncoPep Peptide Vaccine for Tumor Product and Services
    • 2.7.4 OncoPep Peptide Vaccine for Tumor Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.7.5 OncoPep Recent Developments/Updates
  • 2.8 Anergis
    • 2.8.1 Anergis Details
    • 2.8.2 Anergis Major Business
    • 2.8.3 Anergis Peptide Vaccine for Tumor Product and Services
    • 2.8.4 Anergis Peptide Vaccine for Tumor Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.8.5 Anergis Recent Developments/Updates
  • 2.9 Sellas Life Sciences
    • 2.9.1 Sellas Life Sciences Details
    • 2.9.2 Sellas Life Sciences Major Business
    • 2.9.3 Sellas Life Sciences Peptide Vaccine for Tumor Product and Services
    • 2.9.4 Sellas Life Sciences Peptide Vaccine for Tumor Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.9.5 Sellas Life Sciences Recent Developments/Updates

3 Competitive Environment: Peptide Vaccine for Tumor by Manufacturer

  • 3.1 Global Peptide Vaccine for Tumor Sales Quantity by Manufacturer (2021-2026)
  • 3.2 Global Peptide Vaccine for Tumor Revenue by Manufacturer (2021-2026)
  • 3.3 Global Peptide Vaccine for Tumor Average Price by Manufacturer (2021-2026)
  • 3.4 Market Share Analysis (2025)
    • 3.4.1 Producer Shipments of Peptide Vaccine for Tumor by Manufacturer Revenue ($MM) and Market Share (%): 2025
    • 3.4.2 Top 3 Peptide Vaccine for Tumor Manufacturer Market Share in 2025
    • 3.4.3 Top 6 Peptide Vaccine for Tumor Manufacturer Market Share in 2025
  • 3.5 Peptide Vaccine for Tumor Market: Overall Company Footprint Analysis
    • 3.5.1 Peptide Vaccine for Tumor Market: Region Footprint
    • 3.5.2 Peptide Vaccine for Tumor Market: Company Product Type Footprint
    • 3.5.3 Peptide Vaccine for Tumor Market: Company Product Application Footprint
  • 3.6 New Market Entrants and Barriers to Market Entry
  • 3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

  • 4.1 Global Peptide Vaccine for Tumor Market Size by Region
    • 4.1.1 Global Peptide Vaccine for Tumor Sales Quantity by Region (2021-2032)
    • 4.1.2 Global Peptide Vaccine for Tumor Consumption Value by Region (2021-2032)
    • 4.1.3 Global Peptide Vaccine for Tumor Average Price by Region (2021-2032)
  • 4.2 North America Peptide Vaccine for Tumor Consumption Value (2021-2032)
  • 4.3 Europe Peptide Vaccine for Tumor Consumption Value (2021-2032)
  • 4.4 Asia-Pacific Peptide Vaccine for Tumor Consumption Value (2021-2032)
  • 4.5 South America Peptide Vaccine for Tumor Consumption Value (2021-2032)
  • 4.6 Middle East & Africa Peptide Vaccine for Tumor Consumption Value (2021-2032)

5 Market Segment by Type

  • 5.1 Global Peptide Vaccine for Tumor Sales Quantity by Type (2021-2032)
  • 5.2 Global Peptide Vaccine for Tumor Consumption Value by Type (2021-2032)
  • 5.3 Global Peptide Vaccine for Tumor Average Price by Type (2021-2032)

6 Market Segment by Application

  • 6.1 Global Peptide Vaccine for Tumor Sales Quantity by Application (2021-2032)
  • 6.2 Global Peptide Vaccine for Tumor Consumption Value by Application (2021-2032)
  • 6.3 Global Peptide Vaccine for Tumor Average Price by Application (2021-2032)

7 North America

  • 7.1 North America Peptide Vaccine for Tumor Sales Quantity by Type (2021-2032)
  • 7.2 North America Peptide Vaccine for Tumor Sales Quantity by Application (2021-2032)
  • 7.3 North America Peptide Vaccine for Tumor Market Size by Country
    • 7.3.1 North America Peptide Vaccine for Tumor Sales Quantity by Country (2021-2032)
    • 7.3.2 North America Peptide Vaccine for Tumor Consumption Value by Country (2021-2032)
    • 7.3.3 United States Market Size and Forecast (2021-2032)
    • 7.3.4 Canada Market Size and Forecast (2021-2032)
    • 7.3.5 Mexico Market Size and Forecast (2021-2032)

8 Europe

  • 8.1 Europe Peptide Vaccine for Tumor Sales Quantity by Type (2021-2032)
  • 8.2 Europe Peptide Vaccine for Tumor Sales Quantity by Application (2021-2032)
  • 8.3 Europe Peptide Vaccine for Tumor Market Size by Country
    • 8.3.1 Europe Peptide Vaccine for Tumor Sales Quantity by Country (2021-2032)
    • 8.3.2 Europe Peptide Vaccine for Tumor Consumption Value by Country (2021-2032)
    • 8.3.3 Germany Market Size and Forecast (2021-2032)
    • 8.3.4 France Market Size and Forecast (2021-2032)
    • 8.3.5 United Kingdom Market Size and Forecast (2021-2032)
    • 8.3.6 Russia Market Size and Forecast (2021-2032)
    • 8.3.7 Italy Market Size and Forecast (2021-2032)

9 Asia-Pacific

  • 9.1 Asia-Pacific Peptide Vaccine for Tumor Sales Quantity by Type (2021-2032)
  • 9.2 Asia-Pacific Peptide Vaccine for Tumor Sales Quantity by Application (2021-2032)
  • 9.3 Asia-Pacific Peptide Vaccine for Tumor Market Size by Region
    • 9.3.1 Asia-Pacific Peptide Vaccine for Tumor Sales Quantity by Region (2021-2032)
    • 9.3.2 Asia-Pacific Peptide Vaccine for Tumor Consumption Value by Region (2021-2032)
    • 9.3.3 China Market Size and Forecast (2021-2032)
    • 9.3.4 Japan Market Size and Forecast (2021-2032)
    • 9.3.5 South Korea Market Size and Forecast (2021-2032)
    • 9.3.6 India Market Size and Forecast (2021-2032)
    • 9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
    • 9.3.8 Australia Market Size and Forecast (2021-2032)

10 South America

  • 10.1 South America Peptide Vaccine for Tumor Sales Quantity by Type (2021-2032)
  • 10.2 South America Peptide Vaccine for Tumor Sales Quantity by Application (2021-2032)
  • 10.3 South America Peptide Vaccine for Tumor Market Size by Country
    • 10.3.1 South America Peptide Vaccine for Tumor Sales Quantity by Country (2021-2032)
    • 10.3.2 South America Peptide Vaccine for Tumor Consumption Value by Country (2021-2032)
    • 10.3.3 Brazil Market Size and Forecast (2021-2032)
    • 10.3.4 Argentina Market Size and Forecast (2021-2032)

11 Middle East & Africa

  • 11.1 Middle East & Africa Peptide Vaccine for Tumor Sales Quantity by Type (2021-2032)
  • 11.2 Middle East & Africa Peptide Vaccine for Tumor Sales Quantity by Application (2021-2032)
  • 11.3 Middle East & Africa Peptide Vaccine for Tumor Market Size by Country
    • 11.3.1 Middle East & Africa Peptide Vaccine for Tumor Sales Quantity by Country (2021-2032)
    • 11.3.2 Middle East & Africa Peptide Vaccine for Tumor Consumption Value by Country (2021-2032)
    • 11.3.3 Turkey Market Size and Forecast (2021-2032)
    • 11.3.4 Egypt Market Size and Forecast (2021-2032)
    • 11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
    • 11.3.6 South Africa Market Size and Forecast (2021-2032)

12 Market Dynamics

  • 12.1 Peptide Vaccine for Tumor Market Drivers
  • 12.2 Peptide Vaccine for Tumor Market Restraints
  • 12.3 Peptide Vaccine for Tumor Trends Analysis
  • 12.4 Porters Five Forces Analysis
    • 12.4.1 Threat of New Entrants
    • 12.4.2 Bargaining Power of Suppliers
    • 12.4.3 Bargaining Power of Buyers
    • 12.4.4 Threat of Substitutes
    • 12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain

  • 13.1 Raw Material of Peptide Vaccine for Tumor and Key Manufacturers
  • 13.2 Manufacturing Costs Percentage of Peptide Vaccine for Tumor
  • 13.3 Peptide Vaccine for Tumor Production Process
  • 13.4 Industry Value Chain Analysis

14 Shipments by Distribution Channel

  • 14.1 Sales Channel
    • 14.1.1 Direct to End-User
    • 14.1.2 Distributors
  • 14.2 Peptide Vaccine for Tumor Typical Distributors
  • 14.3 Peptide Vaccine for Tumor Typical Customers

15 Research Findings and Conclusion

    16 Appendix

    • 16.1 Methodology
    • 16.2 Research Process and Data Source

    According to our (Global Info Research) latest study, the global Peptide Vaccine for Tumor market size was valued at US$ million in 2025 and is forecast to a readjusted size of US$ million by 2032 with a CAGR of %during review period.
    Peptide Vaccine for Tumor, is an anti-tumor therapeutic vaccine with the most researches, the best effect and the most mature technology among various therapeutic vaccines. Known as subunit vaccines, compared with traditional inactivated and attenuated vaccines, peptide vaccines can not only be used as preventive vaccines against infectious or non-infectious diseases, but also for the treatment of Alzheimer's disease, malignant tumors, etc.; peptide vaccines have become a new strategy for anti-tumor at present, and peptide anti-tumor therapeutic vaccines have accounted for the largest proportion of biotechnology anti-cancer new drugs under development.
    This report is a detailed and comprehensive analysis for global Peptide Vaccine for Tumor market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
    Key Features:
    Global Peptide Vaccine for Tumor market size and forecasts, in consumption value ($ Million), sales quantity (K Dose), and average selling prices (US$/Dose), 2021-2032
    Global Peptide Vaccine for Tumor market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Dose), and average selling prices (US$/Dose), 2021-2032
    Global Peptide Vaccine for Tumor market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Dose), and average selling prices (US$/Dose), 2021-2032
    Global Peptide Vaccine for Tumor market shares of main players, shipments in revenue ($ Million), sales quantity (K Dose), and ASP (US$/Dose), 2021-2026
    The Primary Objectives in This Report Are:
    To determine the size of the total market opportunity of global and key countries
    To assess the growth potential for Peptide Vaccine for Tumor
    To forecast future growth in each product and end-use market
    To assess competitive factors affecting the marketplace
    This report profiles key players in the global Peptide Vaccine for Tumor market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include AmbioPharm, Almac, ACT, Ultimovacs, Marker Therapeutics, Inc., Immatics, OncoPep, Anergis, Sellas Life Sciences, etc.
    This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
    Market Segmentation
    Peptide Vaccine for Tumor market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
    Market segment by Type
    Synthetic Polypeptide Vaccines
    Recombinant Polypeptide Vaccine
    Others
    Market segment by Application
    Infectious Disease Prevention
    Cancer Immunotherapy
    Others
    Major players covered
    AmbioPharm
    Almac
    ACT
    Ultimovacs
    Marker Therapeutics, Inc.
    Immatics
    OncoPep
    Anergis
    Sellas Life Sciences
    Market segment by region, regional analysis covers
    North America (United States, Canada, and Mexico)
    Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
    South America (Brazil, Argentina, Colombia, and Rest of South America)
    Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
    The content of the study subjects, includes a total of 15 chapters:
    Chapter 1, to describe Peptide Vaccine for Tumor product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top manufacturers of Peptide Vaccine for Tumor, with price, sales quantity, revenue, and global market share of Peptide Vaccine for Tumor from 2021 to 2026.
    Chapter 3, the Peptide Vaccine for Tumor competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
    Chapter 4, the Peptide Vaccine for Tumor breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
    Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
    Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Peptide Vaccine for Tumor market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
    Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
    Chapter 13, the key raw materials and key suppliers, and industry chain of Peptide Vaccine for Tumor.
    Chapter 14 and 15, to describe Peptide Vaccine for Tumor sales channel, distributors, customers, research findings and conclusion.

    Buy now